功能变异发现确定了SPRY2,木烟和喘之间的新遗传联系
Arnav Gupta1, Amber Dahlin2, Alejandra Macario3
1National Jewish Health, Denver, Colorado, United States; arnav.gupta@cuanschutz.edu.
American journal of respiratory cell and molecular biology
|September 29, 2025
概括
野火烟雾暴露增加了喘风险. 研究人员发现了特定的基因变异,如RS3861144影响SPRY2,影响呼吸道细胞对木烟颗粒 (WSP) 的反应,为喘发展提供了新的见解.
科学领域:
- 环境健康 环境健康
- 遗传学 是一个遗传学.
- 肺部病理学 肺部病理学
背景情况:
- 气候变化和土地利用政策导致野火烟雾增加.
- 野火烟雾对喘的影响已知,但遗传因素和分子机制尚不清楚.
- 这种知识差距限制了识别高风险个体和制定有针对性的干预措施.
研究的目的:
- 为了确定与喘和木烟颗粒 (WSP) 暴露相关的遗传风险变异.
- 调查WSP影响喘风险的分子机制.
- 探索潜在的遗传生物标志物用于喘风险评估.
主要方法:
- 利用遗传流行病学研究老化 (GERA) 队列来识别遗传变异.
- 具有对木烟颗粒 (WSP) 的基因反应的局部遗传风险变异.
- 测试了空气道上皮细胞中优先变异的等位基依赖转录调节功能.
主要成果:
- 确定了52种与喘和WSP暴露相关的遗传风险变异.
- 在SPRY2的rs3861144变异体中,在对WSP的反应中表现出基因依赖的变化.
- 这些变化涉及互白素-8分泌,ERK激活和细胞修复机制.
结论:
- 野火烟雾颗粒 (WSP) 通过特定的分子通路影响喘风险.
- rs3861144变体和SPRY2基因与WSP介导的喘风险有关.
- 已识别的基因候选人可以作为喘风险分层的临床工具.
相关概念视频
Asthma-II: Pathophysiology and Classification
4.0K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.0K
Asthma-I: Introduction
3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K
Pleiotropy
43.1K
Pleiotropy is the phenomenon in which a single gene impacts multiple, seemingly unrelated phenotypic traits. For example, defects in the SOX10 gene cause Waardenburg Syndrome Type 4, or WS4, which can cause defects in pigmentation, hearing impairments, and an absence of intestinal contractions necessary for elimination. This diversity of phenotypes results from the expression pattern of SOX10 in early embryonic and fetal development. SOX10 is found in neural crest cells that form melanocytes,...
43.1K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K


